Evaluating Vibrio natriegens as a new host for efficient plasmid DNA production in biopharmaceutical applications

The increasing demand for plasmid DNA (pDNA) in biopharmaceutical applications such as gene therapies, DNA vaccines, and mRNA-based treatments has highlighted the need for more efficient and scalable production systems. Traditionally, Escherichia coli has served as the preferred host due to its well-established genetic tools and high-density cultivation capability. However, the search for alternative hosts that offer faster growth, greater metabolic flexibility, and reduced production times has led to growing interest in Vibrio natriegens. This marine bacterium, known as the fastest-growing organism with a doubling time of less than 10 minutes, has shown great potential in synthetic biology, yet its role in large-scale pDNA production remains underexplored.

In this study, the performance of Vibrio natriegens (Vmax) as a pDNA production host was evaluated and compared to E. coli DH5α, both carrying the peGFP plasmid. Cultures were grown over a 6-hour period, followed by plasmid isolation using the High Pure Plasmid Isolation Kit (Roche). Plasmid yields were quantified spectrophotometrically, and the quality was assessed via agarose gel electrophoresis to verify plasmid topology.

The results demonstrated that V. natriegens achieved pDNA yields comparable to and even higher thanthose obtained with E. coli under the same cultivation conditions. Notably, V. natriegens displayed faster growth kinetics, reaching high optical densities within a significantly shorter time frame. This rapid growth could translate into shorter production cycles and higher overall productivity in industrial settings. Furthermore, the comparable plasmid topology observed in both hosts supports the potential of V. natriegensfor downstream applications in gene therapy and vaccine development.

The findings presented in this study underscore the promise of Vibrio natriegens as a next-generation production host for pDNA manufacturing. Ongoing work aims to optimize culture conditions and genetic tools for this organism, ultimately contributing to the development of scalable and sustainable biopharmaceutical production platforms. Future research should explore the integration of V. natriegens into continuous manufacturing processes and assess its performance with different plasmid DNA relevant for clinical applications.